{
    "title": "Obesity, Hypovitaminosis D, and COVID-19",
    "slug": "obesity-hypovitaminosis-d-and-covid-19",
    "aliases": [
        "/Obesity+Hypovitaminosis+D+and+COVID-19+\u2013+April+2022",
        "/13461"
    ],
    "tiki_page_id": 13461,
    "date": "2022-04-08",
    "categories": [
        "Obesity",
        "Virus"
    ],
    "tags": [
        "Obesity",
        "PCOS",
        "Virus",
        "bariatric surgery",
        "blood levels",
        "breathing",
        "cancer",
        "diabetes",
        "health risk",
        "high dose",
        "immunity",
        "influenza",
        "life span",
        "metabolic",
        "mortality",
        "obesity",
        "obesity and cancer",
        "pneumonia",
        "pregnancy",
        "respiratory",
        "sepsis",
        "therapeutic intervention",
        "trauma surgery",
        "virus",
        "virus and obesity",
        "viruses and pregnancy",
        "vitamin d",
        "vitamin d and viruses",
        "vitamin d blood test",
        "weight loss"
    ]
}


{{< toc >}}

---

#### Obesity, Hypovitaminosis D, and COVID-19: the Bermuda Triangle in Public Health

Curr Obes Rep. 2022 Apr 7. [doi: 10.1007/s13679-022-00471-3](https://doi.org/10.1007/s13679-022-00471-3)

Ιrene Karampela 1, Natalia Vallianou 2, Faidon Magkos 3, Caroline M Apovian 4, Μaria Dalamaga 5

<img src="https://d378j1rmrlek7x.cloudfront.net/attachments/jpeg/one-third.jpg" alt="image" width="600">

<img src="https://d378j1rmrlek7x.cloudfront.net/attachments/jpeg/triangle-table.jpg" alt="image" width="900">

Purpose of review: The COVID-19 pandemic has challenged public health to a significant extent by markedly increasing morbidity and mortality. Evidence suggests that obesity and hypovitaminosis D constitute important risk factors for SARS-CoV-2 infection, severity of disease, and poor outcomes. Due to their high prevalence globally, obesity and hypovitaminosis D are considered pandemics. This review presents current epidemiologic and genetic data linking obesity, hypovitaminosis D, and COVID-19, highlighting the importance of the convergence of three pandemics and their impact on public health. We also briefly summarize potential mechanisms that could explain these links.

Recent findings: Epidemiologic data have shown that obesity is an independent risk factor for COVID-19, severe disease and death, and genetic evidence has suggested a causal association between obesity-related traits and COVID-19 susceptibility and severity. Additionally, obesity is independently associated with hypovitaminosis D, which is highly prevalent in subjects with obesity. Hypovitaminosis D is independently associated with a higher risk for COVID-19, severity, hospitalization, infectious complications, acute respiratory distress syndrome, and poor outcomes. However, genome-wide association studies have not revealed any causal association between vitamin D levels and the risk for COVID-19, while there is no robust evidence for a beneficial role of vitamin D supplementation in the prevention and treatment of COVID-19. In the context of the ongoing COVID-19 pandemic, the epidemiologic impact of obesity and hypovitaminosis D is emphasized. Efforts to increase public awareness and reinforce preventive and therapeutic measures against obesity and hypovitaminosis D are strongly required.

 **<i class="fas fa-file-pdf" style="margin-right: 0.3em;"></i><a href="https://d378j1rmrlek7x.cloudfront.net/attachments/pdf/obesity-hypovitaminosis-d-and-covid-19---the-bermuda-triangle.pdf">Download the PDF from VitaminDWiki</a>** 

##### References

Zafgen Inc. outside of the funded work. CMA reports receiving grant funding from NIH, PCORI and Novo Nordisk out­side of the funded work. No other disclosures are reported.

{ANAME()}bookmark1{ANAME} **References** 

{ANAME()}bookmark2{ANAME}Papers of particular interest, published recently, have been highlighted as: {ANAME()}bookmark3{ANAME}• Of importance •• Of major importance

<span>[#_19]</span>     World Health Organization. WHO coronavirus (COVID-19) dashboard. Available from: [https://covid19.who.int/](https://covid19.who.int/) . <span>[Accessed 8 Nov 2021]</span>.

{ANAME()}_138{ANAME}<span>[#_20]</span>      Kalyanaraman Marcello R, Dolle J, Grami S, Adule R, Li Z, Tatem K, et al. New York city health + hospitals COVID-19 population health data team. Characteristics and outcomes of COVID-19 patients in New York city’s public hospital system. PLoS One 2020;15(12): e0243027. [https://doi.org/10.1371/journal.pone.0243027](https://doi.org/10.1371/journal.pone.0243027).

{ANAME()}_141{ANAME}<span>[#_21]</span>      Chawla D, Rizzo S, Zalocusky K, Keebler D, Chia J, Lindsay L, et al. Descriptive epidemiology of 16,780 hospitalized COVID- 19 patients in the United States. 2020:2020.07.17.20156265. medRxiv. [https://doi.org/10.1101/2020.07.17.20156265](https://doi.org/10.1101/2020.07.17.20156265).

{ANAME()}_144{ANAME}<span>[#_22]</span>      Vallianou NG, Evangelopoulos A, Kounatidis D, Stratigou T, Christodoulatos GS, Karampela I, et al. Diabetes mellitus and SARS-CoV-2 infection: pathophysiologic mechanisms and implications in management. Curr Diabetes Rev. 2020. [https://](https://doi.org/10.2174/1573399817666210101110253) [doi.org/10.2174/1573399817666210101110253](https://doi.org/10.2174/1573399817666210101110253).

{ANAME()}_148{ANAME}<span>[#_23]</span> » Dalamaga M, Christodoulatos GS, Karampela I, Vallianou N, Apovian CM. Understanding the co-epidemic of obesity and COVID-19: current evidence, comparison with previous epi­demics, mechanisms, and preventive and therapeutic perspec­tives. Curr Obes Rep. 2021:1-30.  [s13679-021-00436-y](https://doi.org/10.1007/s13679-021-00436-y). This interesting review summarizes current epidemiologic data on the association between obe­sity and COVID-19, compares data from previous pandemics and highlights the pathophysiologic role of obesity-related meta-inflammation with regard to COVID-19.

6.      Obesity: preventing and managing the global epidemic: report of a WHO Consultation on Obesity, Geneva, 3-5 June 1997. World Health Organization. Available form: [https://apps.who.int/iris/](https://apps.who.int/iris/handle/10665/63854) [handle/10665/63854](https://apps.who.int/iris/handle/10665/63854). <span>[Accessed 17 July 2021]</span>

7.      Cashman KD, Vitamin D. deficiency: defining, prevalence, causes, and strategies of addressing. Calcif Tissue Int. 2020;106:14-29. [https://doi.org/10.1007/s00223-019-00559-4](https://doi.org/10.1007/s00223-019-00559-4).

8.      Hughes DA, Norton R. Vitamin D and respiratory health. Clin Exp Immunol. 2009;158(1):20-5.[https://doi.org/10.1111/j.](https://doi.org/10.1111/j.1365-2249.2009.04001.x) [1365-2249.2009.04001.x](https://doi.org/10.1111/j.1365-2249.2009.04001.x).

9.   » Jolliffe DA, Camargo CA Jr, Sluyter JD, Aglipay M, Aloia JF, Ganmaa D, et al. Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta­analysis of aggregate data from randomised controlled trials. Lancet Diabetes Endocrinol. 2021;9(5):276-292. [https://doi.](https://doi.org/10.1016/S2213-8587(21)00051-6) [org/10.1016/S2213-8587(21)00051-6](https://doi.org/10.1016/S2213-8587(21)00051-6). This meta-analysis of 46 RCTs and more than 48,400 participants suggests that vitamin D supplementation is safe and is associated with a small reduction in the risk of acute respiratory infections.

10.    Burn E, You SC, Sena AG, Kostka K, Abedtash H, Abrahao MTF, et al. An international characterisation of patients hos­pitalised with COVID-19 and a comparison with those previ­ously hospitalised with influenza. medRxiv. 2020. [https://doi.](https://doi.org/10.1101/2020.04.22.20074336) [org/10.1101/2020.04.22.20074336](https://doi.org/10.1101/2020.04.22.20074336).

11.    Sattar N, Valabhji J. Obesity as a risk factor for severe COVID- 19: summary of the best evidence and implications for health care. Curr Obes Rep. 2021;10(3):282-9. [https://doi.org/10.](https://doi.org/10.1007/s13679-021-00448-8) [1007/s 13679-021-00448-8](https://doi.org/10.1007/s13679-021-00448-8).

12.    Gu T, Mack JA, Salvatore M, Sankar SP, Valley TS, Singh K, et al. COVID-19 outcomes, risk factors and associations by race: a comprehensive analysis using electronic health records data in Michigan Medicine. medRxiv. 2020. [https://doi.org/10.](https://doi.org/10.1101/2020.06.16.20133140) [1101/2020.06.16.20133140](https://doi.org/10.1101/2020.06.16.20133140).

13.   »» Gao M, Piernas C, Astbury NM, Hippisley-Cox J, O’Rahilly S, Aveyard P, et al. Associations between body-mass index and COVID-19 severity in 6-9 million people in England: a prospective, community-based, cohort study. Lancet Diabetes Endocrinol. 2021. [https://doi.org/10.1016/S2213-8587(21)](https://doi.org/10.1016/S2213-8587(21)00089-9) [00089-9 ](https://doi.org/10.1016/S2213-8587(21)00089-9). This large, prospective, community-based, cohort study in more than 6.9 million participants in England, UK demonstrated a J-shaped association between BMI and hos­pitalization due to COVID-19 with a nadir at BMI of 23 kg/ m{ANAME()}_19{ANAME}<span>[#_135{SUP()}1{SUP}]</span><sup> </sup>{ANAME()}_20{ANAME}<span>[#_138{SUP()}2{SUP}]</span><sup> </sup>{ANAME()}_21{ANAME}<span>[#_141{SUP()}3{SUP}]</span><sup> </sup>{ANAME()}_22{ANAME}<span>[#_144{SUP()}4{SUP}]</span><sup> </sup>{ANAME()}_23{ANAME}<span>[#_148{SUP()}5{SUP}]</span> and a linear increase in ICU admission across the whole BMI range, independently of obesity-related comorbidities. The study also points out that the effect of increasing BMI to the relative risk for severe and critical COVID-19 is higher in adults < 40 years and those of Black ethnicity.

14.    Popkin BM, Du S, Green WD, Beck MA, Algaith T, Herbst CH, et al. Individuals with obesity and COVID-19: a global perspec­tive on the epidemiology and biological relationships. Obes Rev. 2020;21: e13128. [https://doi.org/10.1111/obr.13128](https://doi.org/10.1111/obr.13128).

15.    Soeroto AY, Soetedjo NN, Purwiga A, Santoso P, Kulsum ID, Suryadinata H, et al. Effect of increased BMI and obesity on the outcome of COVID-19 adult patients: a systematic review and meta-analysis. Diabetes Metab Syndr. 2020;14:1897-904. [https://doi.org/10.1016/)'.dsx.2020.09.029](https://doi.org/10.1016/j.dsx.2020.09.029).

16.    Yang J, Tian C, Chen Y, Zhu C, Chi H, Li J. Obesity aggravates COVID-19: an updated systematic review and meta-analysis. J Med Virol. 2020. [https://doi.org/10.1002/jmv.26677](https://doi.org/10.1002/jmv.26677).

17.    Chu Y, Yang J, Shi J, Zhang P, Wang X. Obesity is associated with increased severity of disease in COVID-19 pneumonia: a systematic review and meta-analysis. Eur J Med Res. 2020;25:64. [https ://doi.org/10.1186/s40001 -020-00464-9](https://doi.org/10.1186/s40001-020-00464-9).

18.     Chang TH, Chou CC, Chang LY. Effect of obesity and body mass index on coronavirus disease 2019 severity: a systematic review and meta-analysis. Obes Rev. 2020;21(11): e13089. [https://doi.org/10.1111/obr. 13089](https://doi.org/10.1111/obr.13089).

19.     Foldi M, Farkas N, Kiss S, Zadori N, Vancsa S, Szako L, et al. Obesity is a risk factor for developing critical condition in COVID-19 patients: a systematic review and meta-analysis. Obes Rev. 2020;21: e13095. [https://doi.org/10.1111/obr.13095](https://doi.org/10.1111/obr.13095).

20.     Malik P, Patel U, Patel K, Martin M, Shah C, Mehta D, et al. Obesity a predictor of outcomes of COVID-19 hospitalized patients-a systematic review and meta-analysis. J Med Virol. 2021;93(2):1188-93. [https://doi.org/10.1002/jmv.26555](https://doi.org/10.1002/jmv.26555).

21.     Hoong CWS, Hussain I, Aravamudan VM, Phyu EE, Lin JHX, Koh H. Obesity is associated with poor covid-19 outcomes: a systematic review and meta-analysis. Horm Metab Res. 2021;53(2):85-93. [https://doi.org/10.1055/a-1326-2125](https://doi.org/10.1055/a-1326-2125).

22.     Seidu S, Gillies C, Zaccardi F, Kunutsor SK, Hartmann-Boyce J,   Yates T, et al. The impact of obesity on severe disease and mortality in people with SARS-CoV-2: a systematic review and meta-analysis. Endocrinol Diabetes Metab. 2020;4(1): e00176. [https://doi.org/10.1002/edm2.176](https://doi.org/10.1002/edm2.176).

23.     Hendren NS, de Lemos JA, Ayers C, Das SR, Rao A, Carter S, et al. Association of body mass index and age with morbidity and mortality in patients hospitalized with COVID-19: results from the American Heart Association COVID-19 Cardiovascu­lar Disease Registry. Circulation. 2021;143:135-44. [https ://doi.](https://doi.org/10.1161/circulationaha.120.051936) [or g/10.1161 /circulationaha. 120.051936](https://doi.org/10.1161/circulationaha.120.051936).

24.     Eastment MC, Berry K, Locke E, Green P, O’Hare A, Crothers K,   et al. Body mass index (BMI) and outcomes of SARS-CoV-2 among US veterans. Obesity (Silver Spring). 2020. [https://doi.](https://doi.org/10.1002/oby.23111) [org/10.1002/oby.23111](https://doi.org/10.1002/oby.23111).

25.     Aung N, Khanji MY, Munroe PB, Petersen SE. Causal infer­ence for genetic obesity, cardiometabolic profile and COVID-19 susceptibility: a Mendelian randomization study. Front Genet. 2020;11: 586308. [https://doi.org/10.3389/fgene.2020.586308](https://doi.org/10.3389/fgene.2020.586308).

26.     Leong A, Cole JB, Brenner LN, Meigs JB, Florez JC, Mercader JM. Cardiometabolic risk factors for COVID-19 susceptibility and severity: a Mendelian randomization analysis. PLoS Med. 2021;18:e1003553

27.   »» Zhu Z, Hasegawa K, Ma B, Fujiogi M, Camargo CA Jr, Liang L,   Association of obesity and its genetic predisposition with the risk of severe COVID-19: analysis of population-based cohort data. Metabolism. 2020;112:154345. [https://doi.org/10.1016/).](https://doi.org/10.1016/j.metabol.2020.154345) [metabol.2020.154345](https://doi.org/10.1016/j.metabol.2020.154345). In this study, the analysis of data from almost 0.5 million people from the UK Biobank showed that individuals with higher than normal BMI were at increased risk for severe COVID-19 in a dose-response way. For BMI above 25 kg/m<sup>2</sup>, the ORs ranged from 1.40 to 3.30, being higher for BMI > 40 kg/m<sup>2</sup>. Also, the study concluded that central obesity and genetic predisposition for obesity are associated with a higher risk for severe COVID-19.

28.     Muscogiuri G, Pugliese G, Barrea L, Savastano S, Colao A. Com­mentary: obesity: the “Achilles heel” for COVID-19? Metabolism. 2020;108: 154251. [https://doi.org/10.1016/j.metabol.2020.154251](https://doi.org/10.1016/j.metabol.2020.154251).

29.     Kuperberg SJ, Navetta-Modrov B. The role of obesity in the immunopathogenesis of COVID-19 respiratory disease and critical illness. Am J Respir Cell Mol Biol. 2021;65(1):13-21. [https://doi.org/10.1165/rcmb.2020-0236TR](https://doi.org/10.1165/rcmb.2020-0236TR).

30.     Dhurandhar NV, Bailey D, Thomas D. Interaction of obesity and infections. Obes Rev. 2015;16:1017-29. [https://doi.org/10.1111/](https://doi.org/10.1111/obr.12320) [obr.12320](https://doi.org/10.1111/obr.12320).

31.     McLaughlin T, Ackerman SE, Shen L, Engleman E. Role of innate and adaptive immunity in obesity-associated metabolic disease. J Clin Invest. 2017;127:5-13. [https://doi.org/10.1172/](https://doi.org/10.1172/jci88876) [jci88876](https://doi.org/10.1172/jci88876).

32.     Korakas E, Ikonomidis I, Kousathana F, Balampanis K, Kountouri A, Raptis A, et al. Obesity and COVID-19: immune and metabolic derangement as a possible link to adverse clinical outcomes. Am J Physiol Endocrinol Metab. 2020;319:E105-9. [https://doi.org/10.1152/ajpendo.00198.2020](https://doi.org/10.1152/ajpendo.00198.2020).

33.     Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res Clin Pract. 2005;69:29-35. [https://doi.org/](https://doi.org/10.1016/j.diabres.2004.11.007) [10.1016/j.diabres.2004.11.007](https://doi.org/10.1016/j.diabres.2004.11.007).

34.     Karampela I, Christodoulatos GS, Dalamaga M. The role of adipose tissue and adipokines in sepsis: inflammatory and metabolic considerations, and the obesity paradox. Curr Obes Rep. 2019;8(4):434-457. [https://doi.org/10.1007/](https://doi.org/10.1007/s13679-019-00360-2) [s 13679-019-00360-2](https://doi.org/10.1007/s13679-019-00360-2).

35.     Blokhin IO, Lentz SR. Mechanisms of thrombosis in obesity. Curr Opin Hematol. 2013;20:437-44. [https://doi.org/10.1097/](https://doi.org/10.1097/MOH.0b013e3283634443) [MOH.0b013e3283634443](https://doi.org/10.1097/MOH.0b013e3283634443).

36.     Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS cor- onavirus-induced lung injury. Nat Med. 2005;11:875-9. [https://](https://doi.org/10.1038/nm1267) [doi.org/10.1038/nm1267](https://doi.org/10.1038/nm1267).

37.     van der Heijden DJ, van Leeuwen MAH, Janssens GN, Lenzen MJ, van de Ven PM, Eringa EC, et al. Body mass index is asso­ciated with microvascular endothelial dysfunction in patients with treated metabolic risk factors and suspected coronary artery disease. J Am Heart Assoc. 2017;6. [https://doi.org/10.1161/jaha.](https://doi.org/10.1161/jaha.117.006082) [117.006082](https://doi.org/10.1161/jaha.117.006082).

38.     Kruglikov IL, Scherer PE. The role of adipocytes and adipocyte like cells in the severity of COVID-19 infections. Obesity (Silver Spring). 2020;28:1187-90. [https://doi.org/10.1002/oby.22856](https://doi.org/10.1002/oby.22856).

39.     World Health Organization. Obesity and overweight. Geneva, Switzerland: World Health Organization. Available form: [https://](https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight) [www.who.int/news-room/fact-sheets/detail/obesity-and-overweight](https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight). <span>[Accessed 17 July 2021]</span>

40.     Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes. 2008;32:1431- 7. [https://doi.org/10.1038/ijo.2008.102](https://doi.org/10.1038/ijo.2008.102).

41.     Roth J, Qiang X, Marban SL, Redelt H, Lowell BC. The obesity pandemic: where have we been and where are we going? Obes Res. 2004;12(Suppl 2):88S-101S. [https://doi.org/10.1038/oby.](https://doi.org/10.1038/oby.2004.273) [2004.273](https://doi.org/10.1038/oby.2004.273).

42.     Koliaki C, Liatis S, Dalamaga M, Kokkinos A. Sarcopenic obe­sity: epidemiologic evidence, pathophysiology, and therapeutic perspectives. Curr Obes Rep. 2019;8(4):458-71. [https://doi.org/](https://doi.org/10.1007/s13679-019-00359-9) [10.1007/s 13679-019-00359-9](https://doi.org/10.1007/s13679-019-00359-9).

43.     Hill MA, Sowers JR, Mantzoros CS. Commentary: COVID- 19 and obesity pandemics converge into a syndemic requiring urgent and multidisciplinary action. Metabolism. 2020; 114: 154408. [https://doi.org/10.1016/](https://doi.org/10.1016/j.metabol.2020.154408)'.metabol.2020.154408].

44.   » Karampela I, Sakelliou A, Vallianou N, Christodoulatos GS, Magkos F, Dalamaga M. Vitamin D and obesity: current evi­dence and controversies. Curr Obes Rep. 2021;10(2):162-180. [https://doi.org/10.1007/s13679-021-00433-1](https://doi.org/10.1007/s13679-021-00433-1). This review summarizes current evidence from meta-analyses regarding vitamin D status in obesity, weight loss and post-bariatric surgery, highlights important methodological limitations of relevant studies, and discusses potential pathophysiologic mechanisms and important controversies. The authors con­clude that obesity is associated with low vitamin D status, but weight loss has little effect on improving vitamin D lev­els. Moreover, vitamin D supplementation is not associated with weight loss, while it has shown contradicting results after bariatric surgery.

45.     Pereira-Santos M, Costa PR, Assis AM, Santos CA, Santos DB. Obesity and vitamin D deficiency: a systematic review and meta­analysis. Obes Rev. 2015;16:341-9. [https://doi.org/10.1111/obr.](https://doi.org/10.1111/obr.12239) [12239](https://doi.org/10.1111/obr.12239).

46.     Rafiq S, Jeppesen PB. Body mass index, vitamin D, and type 2 diabetes: a systematic review and meta-analysis. Nutrients. 2018;10:1182. [https://doi.org/10.3390/nu10091182](https://doi.org/10.3390/nu10091182).

47.     Saneei P, Salehi-Abargouei A, Esmaillzadeh A. Serum 25-hydroxy vitamin D levels in relation to body mass index: a systematic review and meta-analysis. Obes Rev. 2013;14:393- 404. [https://doi.org/10.1111/obr. 12016](https://doi.org/10.1111/obr.12016).

48.   « Vimaleswaran KS, Berry DJ, Lu C, Tikkanen E, Pilz S, Hiraki LT, et al. Causal relationship between obesity and vitamin D sta­tus: bidirectional Mendelian randomization analysis of multiple cohorts. PLoS Med. 2013;10:e1001383. [https://doi.org/10.1371/](https://doi.org/10.1371/journal.pmed.1001383) [journal.pmed. 1001383](https://doi.org/10.1371/journal.pmed.1001383). This seminal study investigated the causality and direction of the association between BMI and vitamin D, by using a bi-directional Mendelian randomiza­tion analysis. In more than 42,000 participants from 21 adult cohorts, 12 BMI-related SNPs and 4 vitamin D-related SNPs were studied. The analysis showed that a higher BMI leads to lower vitamin D, while lower vitamin D has a rather small if any effect on increasing BMI.

49.     Golzarand M, HollisBW, Mirmiran P,Wagner CL, Shab-Bidar S. Vitamin D supplementation and body fat mass: a systematic review and meta-analysis. Eur J Clin Nutr. 2018;72:1345-57. [https://doi.org/10.1038/s41430-018-0132-z](https://doi.org/10.1038/s41430-018-0132-z).

50.     Bacopoulou F, Kolias E, Efthymiou V, Antonopoulos CN, Charmandari E. Vitamin D predictors in polycystic ovary syndrome: a meta-analysis. Eur J Clin Investig. 2017;47:746-55.[https://doi.org/](https://doi.org/10.1111/eci.12800) [10.1111/eci.12800](https://doi.org/10.1111/eci.12800).

51.     Shanmugalingam T, Crawley D, Bosco C, Melvin J, Rohrmann S, Chowdhury S, et al. Obesity and cancer: the role of vita­min D. BMC Cancer. 2014;14:712. [https://doi.org/10.1186/](https://doi.org/10.1186/1471-2407-14-712) [1471-2407-14-712](https://doi.org/10.1186/1471-2407-14-712).

52.   « Jiang X, Ge T, Chen CY. The causal role of circulating vitamin D concentrations in human complex traits and diseases: a large- scale Mendelian randomization study. Sci Rep. 2021;11(1):184. [https://doi.org/10.1038/s41598-020-80655-w](https://doi.org/10.1038/s41598-020-80655-w). This is a large, genome-wide association study on more than 400,000 white British UK Biobank participants and more than 130 vitamin D-related SNPs that failed to demonstrate any causal effect of vitamin D on anthropometric traits and obesity.

53.     Abioye AI, Bromage S, Fawzi W. Effect of micronutrient sup­plements on influenza and other respiratory tract infections among adults: a systematic review and meta-analysis. BMJ Glob Health. 2021;6(1): e003176. [https://doi.org/10.1136/](https://doi.org/10.1136/bmjgh-2020-003176) [bmjgh-2020-003176](https://doi.org/10.1136/bmjgh-2020-003176).

54.     Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. 2017;356: i6583. [https://doi.](https://doi.org/10.1136/bmj.i6583) [org/10.1136/bmj.i6583](https://doi.org/10.1136/bmj.i6583).

55.     Thickett DR, Moromizato T, Litonjua AA, Amrein K, Quraishi SA, Lee-Sarwar KA, et al. Association between prehospi­tal vitamin D status and incident acute respiratory failure in critically ill patients: a retrospective cohort study. BMJ Open Respir Res. 2015;2(1): e000074. [https://doi.org/10.1136/](https://doi.org/10.1136/bmjresp-2014-000074) [bmjresp-2014-000074](https://doi.org/10.1136/bmjresp-2014-000074).

56.     Braun A, Chang D, Mahadevappa K, Gibbons FK, Liu Y, Giovannucci E, et al. Association of low serum 25-hydroxyvitamin D levels and mortality in the critically ill. Crit Care Med. 2011;39(4):671-7. [https://](https://doi.org/10.1097/CCM.0b013e318206ccdf) [doi.org/10.1097/CCM.0b013e318206ccdf](https://doi.org/10.1097/CCM.0b013e318206ccdf).

57.     Honardoost M, Ghavideldarestani M, Khamseh ME. Role of vitamin D in pathogenesis and severity of COVID-19 infection.

Arch Physiol Biochem. 2020:1-7. [https://doi.org/10.1080/13813](https://doi.org/10.1080/13813455.2020.1792505) [455.2020.1792505](https://doi.org/10.1080/13813455.2020.1792505).

58.     Malek MA. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: implications for a potential treatment for COVID-19. Rev Med Virol. 2020;30(5): e2119. [https://doi.org/10.1002/rmv.2119](https://doi.org/10.1002/rmv.2119).

59.     Brice DC, Diamond G. Antiviral activities of human host defense peptides. Curr Med Chem. 2020;27(9):1420- 1443. [https://doi.org/10.2174/0929867326666190805151654](https://doi.org/10.2174/0929867326666190805151654)

60.     Bilezikian JP, Bikle D, Hewison M, Lazaretti-Castro M, Formenti AM, Gupta A, et al. Mechanisms in endocrinology: vitamin D and COVID-19. Eur J Endocrinol. 2020;183(5):R133-47. [https://](https://doi.org/10.1530/EJE-20-0665) [doi.org/10.1530/EJE-20-0665](https://doi.org/10.1530/EJE-20-0665).

61.   •• Kaufman HW, Niles JK, Kroll MH, Bi C, Holick MF. SARS-CoV-2 positivity rates associated with circulating 25- hydroxyvitamin D levels. PLoS One. 2020;15(9):e0239252. [https://doi.org/10.1371/journal.pone.0239252](https://doi.org/10.1371/journal.pone.0239252). In this large US study on over 190,000 patients, a strong association between low vitamin D and risk for SARS-CoV-2 infection has been found which remained significant after adjust­ment for age, gender, race and latitude.

62.     Infante M, Buoso A, Pieri M, Lupisella S, Nuccetelli M, Bernardini S, et al. Low vitamin D status at admission as a risk factor for poor survival in hospitalized patients with COVID- 19: an Italian retrospective study. J Am Coll Nutr. 2021:1-16. [https://doi.org/10.1080/07315724.2021.1877580](https://doi.org/10.1080/07315724.2021.1877580).

63.     Jain A, Chaurasia R, Sengar NS, Singh M, Mahor S, Narain S.   Analysis of vitamin D level among asymptomatic and criti­cally ill COVID-19 patients and its correlation with inflam­matory markers. Sci Rep. 2020;10(1):20191. [https://doi.org/](https://doi.org/10.1038/s41598-020-77093-z) [10.1038/s41598-020-77093-z](https://doi.org/10.1038/s41598-020-77093-z).

64.     Liu N, Sun J, Wang X, Zhang T, Zhao M, Li H. Low vita­min D status is associated with coronavirus disease 2019 out­comes: a systematic review and meta-analysis. Int J Infect Dis. 2021;104:58-64. [https://doi.org/10.1016/j.ijid.2020.12.077](https://doi.org/10.1016/j.ijid.2020.12.077).

65.     Wang Z, Joshi A, Leopold K, Jackson S, Christensen S, Nayfeh T,   et al. Association of vitamin D deficiency with COVID-19 infection severity: systematic review and meta-analysis. Clin Endocrinol (Oxf). 2021. [https://doi.org/10.1111/cen.14540](https://doi.org/10.1111/cen.14540).

66.     Akbar MR, Wibowo A, Pranata R, Setiabudiawan B. Low serum 25-hydroxyvitamin D (vitamin D) level is associated with susceptibility to COVID-19, severity, and mortality: a systematic review and meta-analysis. Front Nutr. 2021;8: 660420. [https://doi.org/10.3389/fnut.2021.660420](https://doi.org/10.3389/fnut.2021.660420).

67.     Petrelli F, Luciani A, Perego G, Dognini G, Colombelli PL, Ghidini A. Therapeutic and prognostic role of vitamin D for COVID-19 infection: a systematic review and meta-analysis of 43 observational studies. J Steroid Biochem Mol Biol. 2021;211: 105883. [https://doi.org/10.1016/josbmb.2021.105883](https://doi.org/10.1016/j.jsbmb.2021.105883).

68.     Pereira M, Dantas Damascena A, Galvao Azevedo LM, de Almeida Oliveira T, da Mota Santana J. Vitamin D deficiency aggravates COVID-19: systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2020:1-9. [https://doi.org/10.1080/10408398.](https://doi.org/10.1080/10408398.2020.1841090) [2020.1841090](https://doi.org/10.1080/10408398.2020.1841090).

69.     Teshome A, Adane A, Girma B, Mekonnen ZA. The impact of vitamin D level on COVID-19 infection: systematic review and meta-analysis. Front Public Health. 2021;9: 624559. [https://doi.](https://doi.org/10.3389/fpubh.2021.624559) [org/10.3389/fpubh.2021.624559](https://doi.org/10.3389/fpubh.2021.624559).

70.     Merzon E, Tworowski D, Gorohovski A, Vinker S, Golan Cohen A, Green I, et al. Low plasma 25(OH) vitamin D level is associ­ated with increased risk of COVID-19 infection: an Israeli pop­ulation-based study. FEBS J. 2020;287(17):3693-702. [https://](https://doi.org/10.1111/febs.15495) [doi.org/10.1111/febs.15495](https://doi.org/10.1111/febs.15495).

71.     Dror AA, Morozov N, Daoud A, Namir Y, Yakir O, Shachar Y, et al. Pre-infection 25-hydroxyvitamin D3 levels and association with severity of COVID-19 illness. PLoS ONE. 2022;17(2): e0263069. [https://doi.org/10.1371/journal.pone.0263069](https://doi.org/10.1371/journal.pone.0263069).

72.     Vassiliou AG, Jahaj E, Orfanos SE, Dimopoulou I, Kotanidou A. Vitamin D in infectious complications in critically ill patients with or without COVID-19. Metabol Open. 2021:100106. [https ://doi.org/10.1016/j. metop.2021.100106](https://doi.org/10.1016/j.metop.2021.100106).

73.     Charoenngam N, Shirvani A, Reddy N, Vodopivec DM, Apovian CM, Holick MF. Association of vitamin D status with hospi­tal morbidity and mortality in adult hospitalized patients with COVID-19. Endocr Pract. 2021;27(4):271-8. [https://doi.org/10.](https://doi.org/10.1016/j.eprac.2021.02.013) [1016/j.eprac.2021.02.013](https://doi.org/10.1016/j.eprac.2021.02.013).

74.     Borsche L, Glauner B, von Mendel J. COVID-19 mortality risk correlates inversely with vitamin D3 status, and a mor­tality rate close to zero could theoretically be achieved at 50 ng/mL 25(OH)D3: results of a systematic review and meta­analysis. Nutrients. 2021;13(10):3596. [https://doi.org/10.3390/](https://doi.org/10.3390/nu13103596) [nu13103596](https://doi.org/10.3390/nu13103596).

75.     Butler-Laporte G, Nakanishi T, Mooser V, Morrison DR, Abdullah T, Adeleye O, et al. Vitamin D and COVID-19 susceptibility and severity in the COVID-19 host genetics initiative: a Mendelian randomization study. PLoS Med. 2021;18(6): e1003605. [https://](https://doi.org/10.1371/journal.pmed.1003605) [doi.org/10.1371/journal.pmed.1003605](https://doi.org/10.1371/journal.pmed.1003605).

76.     Rastogi A, Bhansali A, Khare N, Suri V, Yaddanapudi N, Sachdeva N, Puri GD, Malhotra P. Short term, high-dose vitamin D sup­plementation for COVID-19 disease: a randomised, placebo­controlled, study (SHADE study). Postgrad Med J. 2020:post- gradmedj-2020-139065.[https://doi.org/10.1136/postgradmedj-](https://doi.org/10.1136/postgradmedj-2020-139065) [2020-139065](https://doi.org/10.1136/postgradmedj-2020-139065).

77.     Lakkireddy M, Gadiga SG, Malathi RD, Karra ML, Raju ISS- VPM, Ragini, et al. Impact of daily high dose oral vitamin D therapy on the inflammatory markers in patients with COVID 19 disease. Sci Rep. 2021;11(1):10641. [https://doi.org/10.1038/](https://doi.org/10.1038/s41598-021-90189-4) [s41598-021-90189-4](https://doi.org/10.1038/s41598-021-90189-4).

78.     Ling SF, Broad E, Murphy R, Pappachan JM, Pardesi-Newton S, Kong MF, et al. High-dose cholecalciferol booster therapy is associated with a reduced risk of mortality in patients with COVID-19: a cross-sectional multi-centre observational study. Nutrients. 2020;12(12):3799. [https://doi.org/10.3390/](https://doi.org/10.3390/nu12123799) [nu12123799](https://doi.org/10.3390/nu12123799).

79.     Giannini S, Passeri G, Tripepi G, Sella S, Fusaro M, Arcidiacono G, et al. Effectiveness of in-hospital cholecalciferol use on clinical outcomes in comorbid COVID-19 patients: a hypothesis-generating study. Nutrients. 2021;13(1):219. [https://doi.org/10.3390/nu13010219](https://doi.org/10.3390/nu13010219).

80.     Annweiler C, Hanotte B, Grandin de l'Eprevier C, Sabatier JM, Lafaie L, Celarier T. Vitamin D and survival in COVID-19 patients: a quasi-experimental study. J Steroid Biochem Mol Biol. 2020;204:105771. [https://doi.org/10.1016/j.jsbmb.2020.105771](https://doi.org/10.1016/j.jsbmb.2020.105771).

81.    Murai IH, Fernandes AL, Sales LP, Pinto AJ, Goessler KF, Duran CSC, et al. Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial. JAMA. 2021;325(11):1053-1060. [https://doi.org/10.1001/jama.2020.26848](https://doi.org/10.1001/jama.2020.26848). This RCT on 240 hospitalized patients with moderate to severe COVID-19 failed to show any benefit from vitamin D supplementation, regarding hospital length of stay, in-hospital mortality and need for mechanical ventilation.

82.     Pal R, Banerjee M, Bhadada SK, Shetty AJ, Singh B, Vyas A. Vitamin D supplementation and clinical outcomes in COVID- 19: a systematic review and meta-analysis. J Endocrinol Invest. 2021:1-16. [https://doi.org/10.1007/s40618-021-01614-4](https://doi.org/10.1007/s40618-021-01614-4).

83.     Stroehlein JK, Wallqvist J, Iannizzi C, Mikolajewska A, Metzendorf MI, Benstoem C, et al. Vitamin D supplementa­tion for the treatment of COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021;5:CD015043.[https://doi.](https://doi.org/10.1002/14651858.CD015043) [org/10.1002/14651858.CD015043](https://doi.org/10.1002/14651858.CD015043).

84.     Chen J, Mei K, Xie L, Yuan P, Ma J, Yu P, Zhu W, Zheng C, Liu X. Low vitamin D levels do not aggravate COVID-19 risk or death, and vitamin D supplementation does not improve out­comes in hospitalized patients with COVID-19: a meta-analysis and GRADE assessment of cohort studies and RCTs. Nutr J. 2021;20(1):89. [https://doi.org/10.1186/s12937-021-00744-y](https://doi.org/10.1186/s12937-021-00744-y).

85.     Rubin R. Sorting out whether vitamin D deficiency raises COVID-19 risk. JAMA. 2021;325(4):329-30. [https://doi.org/](https://doi.org/10.1001/jama.2020.24127) [10.1001/jama.2020.24127](https://doi.org/10.1001/jama.2020.24127).

86.   « Li S, Cao Z, Yang H, Zhang Y, Xu F, Wang Y. Metabolic healthy obesity, vitamin D status, and risk of COVID-19. Aging Dis. 2021;12(1):61-71. [https://doi.org/10.14336/AD.2020.1108](https://doi.org/10.14336/AD.2020.1108). This study used data from more than 350,000 UK Biobank partici­pants to investigate whether the addition of metabolic disorders and vitamin D insufficiency increased obesity associations with COVID-19 hospitalization, confirmed COVID-19, and severe COVID-19. The multivariate logistic regression analysis showed that obesity combined with metabolic disorders and hypovitaminosis D is associated with a significantly increased risk of COVID-19 severity, especially in adults 65 years and older.

87.     Dalamaga M, Muscogiuri G, Paganitsa G, Parvouleskou G, Syriou V, Karagkoynis P, et al. Adherence to the Mediterranean diet is an independent predictor of circulating vitamin D levels in normal weight and non-smoker adults: an observational cross­sectional study. Int J Food Sci Nutr. 2021:1-13. [https://doi.org/](https://doi.org/10.1080/09637486.2021.1878488) [10.1080/09637486.2021.1878488](https://doi.org/10.1080/09637486.2021.1878488).

88.     Belanger MJ, Hill MA, Angelidi AM, Dalamaga M, Sowers JR, Mantzoros CS. Covid-19 and disparities in nutrition and obe­sity. N Engl J Med. 2020;383(11): e69. [https://doi.org/10.1056/](https://doi.org/10.1056/NEJMp2021264) [NEJMp2021264](https://doi.org/10.1056/NEJMp2021264).

{ANAME()}_135{ANAME}